Congenital hypothyroidism (CH) as a partial or complete loss of function of the thyroid gland affects neonates from birth (
1). In this disease, the function of iodine-containing hormones that have an important role in metabolism, regulating growth, and brain development is disrupted due to inadequate thyroid hormone production that can be resulted from an inborn error of thyroid metabolism, defect in the gland, and iodine deficiency (
2,
3). The clinical manifestations of CH are often subtle and, in more cases, not present at birth, likely because of the transplacental passage of maternal thyroid hormones. Increased sleep and decreased activity, feeding difficulty, constipation, and prolonged jaundice are common symptoms of children with CH (
4,
5). According to new evidence, CH can be a risk factor for central hearing process disorders (
6). This endocrine disorder can be detected on newborn screening, and infants who are identified in the first month have the best prognosis for optimal mental development (
7).
Newborn screening programs for CH, which are primarily implemented in developed countries, provide the opportunity to investigate the pathogenesis and etiology of CH (
8). Prior to the newborn screening program, the diagnosis of CH was based on clinical signs and symptoms, and the incidence was 1:7,000 to 1:10,000 (
9). According to the current evidence, the recall rates of neonates, vary from 0.01% to 13.3% in different countries (
10). Based on the reports obtained from data of national newborn screening programs in many regions, especially in the developed countries, CH occurs in approximately 1:2000 to 1:4000 newborns in many areas of the world, whereas CH incidence in Iran is higher. In Iran, where CH incidence is 1:650 live births, the national neonatal screening program for CH was established in 2004 and progressively developed all over the country (
11,
12). All the Iranian public health centers that participate in the national screening program are responsible for newborn screening, treatment, and follow-up of children with CH. The success of CH treatment in Iran has been reported in a previous study (
13).
The incidence of CH in Iran is much higher than in many other countries and the global average (
14). Different familial and environmental factors can influence this high incidence. In fact, CH is a multifactorial disease, so that many environmental, familial, and autoimmune factors play a role in its pathogenesis (
15,
16). Previous studies about the role of autoimmune factors in the Iranian population revealed no significant role in the pathogenesis of CH (
17). Undeniably, identifying CH risk factors is crucial to improving the surveillance system of CH in the country and can help policymakers to plan and conduct pertinent intervention programs to control the high occurrence of this congenital disorder in the country. Regarding the environmental factors, the role of iodine deficiency or excess iodine intake was investigated. Iodine deficiency had no significant role in this regard (
15).